Alector provides update on arbitration proceedings with dr. asa abeliovich

South san francisco, calif., nov. 02, 2020 (globe newswire) -- alector, inc. (nasdaq: alec), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that an independent arbitrator issued an interim, confidential decision in favor of the company in its dispute with asa abeliovich, m.d., ph.d., founder and chief executive officer of prevail therapeutics. the arbitrator found dr. abeliovich liable for breach of his consulting agreement with alector and for spoliation based on his destruction of documents relevant to the proceeding. the arbitrator awarded damages for breach of the agreement, and sanctions for the spoliation as well as violation of orders during the proceeding. the monetary amounts of the damages and sanctions will be determined in further proceedings.
ALEC Ratings Summary
ALEC Quant Ranking